Diabetic patients taking Invokana, Farxiga, or Jardiance are on alert over reports that these SGLT2 inhibitors could possibly cause a potentially lethal flesh-eating infection of the genitals. Bloomberg recently reported that SGLT2 inhibitor-induced Fourneir’s gangrene was observed in a dozen patients between March 2013 and May 2018. All cases required surgery and in one case the condition proved fatal. The FDA has said that more ...
Diabetes Drug Linked to Flesh-Eating Genital Infection
Posted September 25, 2018 in Drug and Medical Device Lawsuits | Product News and Recalls
New SGLT2 Inhibitor Joins Troubled Class of Diabetes Drugs
Posted September 16, 2015 in Drug and Medical Device Lawsuits | Product News and Recalls
According to a Nasdaq report, the U.S. Food and Drug Administration (FDA) has approved Eli Lilly and Boehringer Ingelheim’s new type 2 diabetes drug, Synjardy. Synjardy is the latest in a new line of diabetes medications known as sodium-glucose cotransporter-2 inhibitors, called SGLT2 inhibitors for short.
SGLT2 inhibitors help lower patients’ blood sugar by preventing reabsorption of glucose in the kidneys and eliminating excess sugar through ...
continue reading...Diabetic Ketoacidosis Connection Remains despite SGLT2 Inhibitor Trial Results
Posted September 8, 2015 in Product News and Recalls
A recent Reuters article reports that Eli Lilly & Co. and Boehringer Ingelheim have received positive results for their sodium-glucose cotransporter-2 (SGLT2) inhibitor Jardiance. According to a recent drug trial, empagliflozin (Jardiance) can cut patients’ risk of cardiovascular problems like heart attack and stroke. But Jardiance and other SGLT2 inhibitors still cannot seem to escape the shadow of diabetic ketoacidosis, a potentially fatal blood condition to which the new class of diabetes drugs ...
FDA: SGLT2 Inhibitors May Lead to Serious Blood Condition
Posted May 22, 2015 in Product News and Recalls
The U.S. Food and Drug Administration (FDA) has issued a Drug Safety Communication warning that the SGLT2 inhibitors canagliflozin, dapagliflozin, and empagliflozin may result in ketoacidosis, a serious blood condition in which the body produces excess blood acids, or ketones. Ketoacidosis may require hospitalization and in extreme cases can prove fatal. The SLGT2 inhibitors are marketed under the brand names Invokana, Invokamet, Farxiga, Jardiance, Glyxambi, and Xigduo ...
